eClinical Technology and Industy News

Aramis Biosciences Completes Enrollment of its Phase II Clinical Trial Evaluating A197 for the Treatment of Dry Eye Disease

Topline proof of concept data anticipated by Q1 2023

Excerpt from the Press Release:

BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) — Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, today announced the completion of enrollment in its Phase II proof of concept clinical trial evaluating A197, a novel, first-in-class, topical immunomodulatory agent for the treatment of dry eye disease.

“We are very pleased to have completed the enrollment of our Phase II study for A197 and look forward to topline data by the end of the first quarter of 2023,” said David S. Tierney, M.D., Aramis Biosciences’ President and CEO. “We would like to thank the patients who enrolled in the study as well as the clinical investigators and other research staff who have worked diligently to get us to this point.”

About A197-CS-201

The Phase II, multicenter, double-masked, randomized, vehicle-controlled, parallel-group clinical trial (NCT05238597) is designed to evaluate the safety and tolerability as well as explore the efficacy of two doses of A197 ophthalmic solution in 207 patients with dry eye disease. The primary endpoint of the trial measures the change from baseline in corneal fluorescein staining with a key secondary endpoint evaluating eye dryness symptoms using the visual analog scale (VAS). The clinical trial is being conducted across 24 centers in the United States.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?